BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• First Patient Recruited to Promore Pharma’s Clinical Trial Regarding Scarring According to Plan

  Promore Pharma AB announces that the first subject has been included in the company’s phase II study with the company’s drug candidate ensereptide for the prevention of skin scarring.

  February 16, 2022

   · 

  4 min read
• Business

  Interim Report January - December 2021

  The financial year 2021 was an important year for us at Promore Pharma. We made the strategic decision to orient our project regarding ensereptide towards prevention of skin scarring.

  February 16, 2022

   · 

  6 min read
• Pharyngitis Diagnostic Market: Asia Pacific to Lead Global Market

  Pharyngitis is the medical condition that causes inflammation at the back of the throat which is known as pharynx.

  February 16, 2022

   · 

  5 min read
• Mechanical Circulatory Support Devices Market: Increase in incidence of cardiovascular diseases is expected to drive the market

  Mechanical circulatory support includes a range of therapies and devices which aid in rescuing patients from the life-threatening cardiogenic shock.

  February 16, 2022

   · 

  5 min read
• Biotech Bay

  European Commission Approves Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

  Global Blood Therapeutics, Inc. announced the European Commission has granted Marketing Authorization for Oxbryta® for the treatment of hemolytic anemia due to sickle cell disease in adult and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

  February 16, 2022

   · 

  13 min read
• Business

  ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021Conference Call Scheduled for Wednesday, February 23, 2022 at 9:00 AM ET

  ImmuCell Corporation expects to report unaudited financial results for the quarter and year ended December 31, 2021 after the market closes on Tuesday, February 22, 2022.

  February 16, 2022

   · 

  6 min read
• Business

  Cerevel Therapeutics to Report Fourth Quarter 2021 Financial Results and Pipeline Update on Tuesday, March 1, 2022

  Cerevel Therapeutics today announced it will report fourth quarter 2021 financial results on Tuesday, March 1, 2022, before the U.S. financial markets open.

  February 16, 2022

   · 

  4 min read
• Business

  Tetra Bio-Pharma Receives $4.5M from the Ministere de l’Economie et de l’Innovation/Investissement Quebec

  Tetra Bio-Pharma Inc. is proud to announce the approval of a $4.5M CDN participative loan from the ministère de l’Économie et de l’Innovation (MEI) under the BioMed Propulsion Program, managed by Investissement Québec (IQ).

  February 16, 2022

   · 

  5 min read
• Business

  ITM Receives Equity Investment of EUR 25 Million from Strategic Partner Grand Pharma

  Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia.

  February 16, 2022

   · 

  6 min read
• Business

  Merck Announces New Leadership for Human Health Business

  Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new leadership for its Human Health business.

  February 16, 2022

   · 

  5 min read